CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 95 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q3 2020. The put-call ratio across all filers is 0.41 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $195,092,582 | -18.9% | 7,089,120 | +0.0% | 0.02% | -15.0% |
| Q2 2023 | $240,491,429 | -52.8% | 7,087,870 | -50.0% | 0.02% | -13.0% |
| Q1 2023 | $509,554,372 | +61.8% | 14,162,156 | +100.5% | 0.02% | -25.8% |
| Q4 2022 | $314,885,891 | +59.7% | 7,064,974 | +0.7% | 0.03% | +47.6% |
| Q3 2022 | $197,215,000 | +4.3% | 7,015,843 | +0.0% | 0.02% | +10.5% |
| Q2 2022 | $189,074,000 | -20.8% | 7,013,144 | +0.0% | 0.02% | 0.0% |
| Q1 2022 | $238,769,000 | -11.7% | 7,010,253 | +0.2% | 0.02% | -5.0% |
| Q4 2021 | $270,464,000 | -10.8% | 6,999,580 | +24.7% | 0.02% | -16.7% |
| Q3 2021 | $303,172,000 | +2375.3% | 5,615,333 | +1433.0% | 0.02% | +2300.0% |
| Q2 2021 | $12,248,000 | +76.0% | 366,295 | +8.4% | 0.00% | 0.0% |
| Q1 2021 | $6,961,000 | – | 337,900 | +33789900.0% | 0.00% | – |
| Q4 2020 | $0 | -100.0% | 1 | -98.6% | 0.00% | – |
| Q3 2020 | $1,000 | – | 73 | +46.0% | 0.00% | – |
| Q4 2019 | $0 | – | 50 | +150.0% | 0.00% | – |
| Q3 2019 | $0 | – | 20 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ACUTA CAPITAL PARTNERS, LLC | 1,017,524 | $20,961,000 | 7.56% |
| Octagon Capital Advisors LP | 561,398 | $11,565,000 | 4.36% |
| COMMODORE CAPITAL LP | 369,951 | $7,621,000 | 3.04% |
| Opaleye Management Inc. | 985,000 | $20,291,000 | 2.98% |
| VR Adviser, LLC | 1,240,610 | $25,557,000 | 2.77% |
| TSP Capital Management Group, LLC | 359,229 | $7,400,000 | 2.61% |
| RTW INVESTMENTS, LP | 3,908,947 | $80,524,000 | 1.26% |
| Ghost Tree Capital, LLC | 250,000 | $5,150,000 | 1.21% |
| Tri Locum Partners LP | 196,672 | $4,051,000 | 1.00% |
| Redmile Group, LLC | 3,387,788 | $69,788,000 | 0.98% |